Trials / Completed
CompletedNCT00920816
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 492 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axitinib (AG-013736) | axitinib will be given at a starting dose of 5 mg BID with continuous dosing |
| DRUG | Sorafenib | sorafenib will be given at a dose of 400 mg BID continuous dosing |
Timeline
- Start date
- 2009-08-25
- Primary completion
- 2012-07-27
- Completion
- 2021-04-29
- First posted
- 2009-06-15
- Last updated
- 2022-05-06
- Results posted
- 2014-02-04
Locations
125 sites across 14 countries: United States, Bosnia and Herzegovina, Bulgaria, Chile, China, India, Malaysia, Mexico, Philippines, Romania, Russia, South Africa, Taiwan, Ukraine
Source: ClinicalTrials.gov record NCT00920816. Inclusion in this directory is not an endorsement.